Onychomycosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Onychomycosis Treatment Market Trends and it is segmented by Treatment Type (Drugs, Laser Therapy, and Photodynamic Therapy), Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, and Other Types), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The market provides the value (in USD million) for the above segments.

Onychomycosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Onychomycosis Treatment Market Size

Onychomycosis Treatment Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 3.51 Billion
Market Size (2030) USD 4.37 Billion
CAGR (2025 - 2030) 4.46 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Onychomycosis Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Onychomycosis Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Onychomycosis Treatment Market Analysis

The Global Onychomycosis Treatment Market size is estimated at USD 3.51 billion in 2025, and is expected to reach USD 4.37 billion by 2030, at a CAGR of 4.46% during the forecast period (2025-2030).

The onychomycosis treatment landscape is experiencing significant transformation driven by demographic shifts and healthcare evolution. According to the World Health Organization's projections, by 2030, one in every six individuals globally will be aged 60 years or older, with the total elderly population expected to increase from 1 billion in 2020 to 1.4 billion by 2050. This demographic transition is reshaping healthcare priorities and treatment approaches, particularly in developed regions where healthcare infrastructure is more robust. The aging population's increased susceptibility to fungal infections, combined with their typically more complex medical needs, is prompting healthcare providers to adopt more comprehensive treatment strategies.


Technological advancements in onychomycosis therapy modalities are revolutionizing the therapeutic landscape. The integration of laser technology has emerged as a particularly promising development, with an active installed base of more than 80,000 systems globally. These advanced treatment options are providing alternatives to traditional pharmaceutical approaches, especially beneficial for patients with contraindications to systemic antifungal treatments. The emergence of photodynamic therapy and other innovative onychomycosis treatment methods is expanding the therapeutic arsenal available to healthcare providers, offering more personalized treatment options based on individual patient needs and conditions.


Research and development initiatives are driving innovation in treatment methodologies, with a significant focus on improving drug delivery systems and developing more effective therapeutic compounds. Clinical trials are exploring novel approaches, including nanotechnology-enhanced treatments and combination therapies, aiming to address the challenges of traditional treatments such as long duration and limited efficacy. The pharmaceutical industry's investment in research is yielding promising results, with several new drug formulations and delivery systems in various stages of development, potentially offering more effective nail fungus treatment options in the near future.


Healthcare infrastructure development and increasing access to advanced treatment options are reshaping market dynamics. The establishment of specialized treatment centers and the integration of dermatological services into primary healthcare settings are improving diagnosis rates and treatment accessibility. The onychomycosis market is witnessing a shift towards more integrated care approaches, where multiple treatment modalities are combined to achieve optimal outcomes. This evolution in healthcare delivery systems, coupled with improving insurance coverage for fungal infection treatments, is creating a more conducive environment for market growth and treatment adoption.

Segment Analysis: By Treatment Type

Drugs Segment in Global Onychomycosis Treatment Market

The onychomycosis drugs market continues to dominate the global onychomycosis treatment market, holding approximately 81% of the market share in 2024. This substantial market position is attributed to the high efficacy and easy availability of pharmaceutical products for treating onychomycosis. The segment encompasses various drug types, including terbinafine, ciclopirox, fluconazole, and efinaconazole, which remain the first-line choice of treatment owing to their consistently high success rates. The widespread acceptance of these medications among healthcare providers and patients, coupled with their established safety profiles and documented clinical outcomes, has solidified their position as the primary treatment modality. Additionally, the extensive distribution networks and the availability of both branded and generic options have made these treatments more accessible to patients across different geographical regions and economic segments.

Market Analysis of Global Onychomycosis Treatment Market: Chart for By Treatment Type

Photodynamic Therapy Segment in Global Onychomycosis Treatment Market

The photodynamic therapy (PDT) segment is emerging as the fastest-growing treatment option in the onychomycosis treatment market for the period 2024-2029. This growth is driven by several advantages offered by PDT, including its broad spectrum of action, effectiveness independent of patterns of antimicrobial resistance, and compatibility with other antibiotic and antifungal drugs in combination therapies. The treatment modality is gaining particular traction among patients with contraindications for systemic antifungal treatment, as it offers a non-invasive alternative with minimal side effects. The technology's ability to specifically deliver photosensitizer to the infected area while sparing adjacent healthy tissue has made it an increasingly attractive option for both healthcare providers and patients. Furthermore, the advancement in PDT technologies and growing evidence of its efficacy in clinical settings are contributing to its rapid adoption across various healthcare facilities.

Remaining Segments in Treatment Type

The laser therapy segment represents a significant portion of the onychomycosis treatment market, offering a promising alternative for patients seeking non-pharmaceutical interventions. This treatment modality has gained prominence due to its effectiveness in treating onychomycosis in specific patient populations, particularly diabetics, elderly patients with drug intolerance, and those with liver and kidney disease, owing to its minimal side effects. The technology utilizes various types of lasers, including short pulse Nd:YAG lasers, long pulse Nd:YAG lasers, Q-switched lasers, and fractional CO2 lasers, each offering specific advantages in treating different manifestations of the condition. The segment's growth is supported by ongoing technological advancements and increasing adoption in specialized dermatology clinics and healthcare facilities.

Segment Analysis: By Type

Distal Subungual Onychomycosis Segment in Global Onychomycosis Treatment Market

Distal subungual onychomycosis (DSO) continues to dominate the global onychomycosis treatment market, holding approximately 70% of the market share in 2024. This substantial market position is attributed to DSO being the most common clinical pattern of onychomycosis, affecting both toenails and fingernails. The infection typically begins at the hyponychium and progresses proximally through the nail bed, with Trichophyton rubrum being the primary causative organism. The high prevalence of this type is particularly notable in immunocompromised patients and those with diabetes, making it a significant concern for healthcare providers. The segment's dominance is further reinforced by the availability of various treatment options, including both topical and systemic antifungal medications, as well as emerging laser therapies.

White Superficial Onychomycosis Segment in Global Onychomycosis Treatment Market

The white superficial onychomycosis (WSO) segment is projected to exhibit the highest growth rate of approximately 6% during the forecast period 2024-2029. This growth trajectory is primarily driven by the increasing awareness about early diagnosis and topical treatment options for onychomycosis specifically designed for WSO. The segment's expansion is supported by the development of innovative topical treatments that specifically target the nail plate, which is the primary site of invasion in WSO cases. The growth is further accelerated by the rising incidence of WSO in pediatric populations and immunocompromised patients, particularly those with AIDS. Additionally, the segment is benefiting from the introduction of new mechanical removal techniques combined with topical antifungal agents, which have shown promising results in clinical settings.

Remaining Segments in Onychomycosis Treatment Market by Type

The remaining segments in the market include proximal subungual onychomycosis (PSO) and other types of onychomycosis. PSO, while being the least common form in healthy individuals, holds significant clinical importance as it often serves as a marker for immunodeficiency conditions. The other types segment encompasses variants such as total dystrophic onychomycosis and endonyx onychomycosis, each presenting unique challenges in treatment approaches. These segments are particularly relevant in specific patient populations, such as those with HIV/AIDS or other immunocompromising conditions, and continue to drive innovation in targeted therapeutic approaches and treatment modalities.

Global Onychomycosis Treatment Market Geography Segment Analysis

Onychomycosis Treatment Market in North America

The North American onychomycosis market demonstrates robust growth driven by advanced healthcare infrastructure, high disease awareness, and a strong presence of key pharmaceutical companies. The United States, Canada, and Mexico form the key markets in this region, with varying levels of market maturity and healthcare accessibility. The region benefits from extensive research and development activities, favorable reimbursement policies, and increasing adoption of novel treatment options, including laser therapy and photodynamic therapy.

Market Analysis of Global Onychomycosis Treatment Market: Forecasted Growth Rate by Region

Onychomycosis Treatment Market in the United States

The United States dominates the North American onychomycosis market, commanding approximately 40% of the global onychomycosis treatment market. The country's market leadership is attributed to its sophisticated healthcare system, high healthcare expenditure, and the presence of major pharmaceutical companies. The increasing prevalence of diabetes, growing geriatric population, and rising awareness about fungal infections contribute significantly to market growth. The country also leads in clinical trials and research activities related to onychomycosis treatment, with numerous ongoing studies exploring novel therapeutic approaches.

Onychomycosis Treatment Market in Mexico

Mexico emerges as the fastest-growing market in North America, with a projected growth rate of approximately 6% during 2024-2029. The country's market expansion is driven by improving healthcare infrastructure, increasing awareness about fungal infections, and growing accessibility to treatment options. The rising prevalence of diabetes and expanding geriatric population create substantial growth opportunities. Additionally, the country is witnessing increased participation in clinical trials and research activities, particularly in studying the effectiveness of various treatment modalities for onychomycosis.

Onychomycosis Treatment Market in Europe

The European onychomycosis market exhibits steady growth supported by well-established healthcare systems, strong research infrastructure, and high disease awareness levels. Key markets include Germany, France, the United Kingdom, Italy, and Spain, each contributing significantly to the regional market dynamics. The region benefits from advanced treatment options, a strong presence of pharmaceutical companies, and favorable healthcare policies supporting treatment accessibility.

Onychomycosis Treatment Market in Germany

Germany leads the European onychomycosis market, representing approximately 24% of the region's onychomycosis treatment market. The country's market dominance is supported by its robust healthcare system, significant R&D investments, and high adoption of advanced treatment options. The presence of major pharmaceutical companies, extensive clinical research activities, and high disease awareness levels contribute to market growth. The country also demonstrates a strong focus on innovative treatment approaches and maintains high standards in healthcare delivery.

Onychomycosis Treatment Market in France

France exhibits the highest growth potential in Europe, with an expected growth rate of approximately 5% during 2024-2029. The country's market growth is driven by increasing R&D investments, rising prevalence of onychomycosis, and growing adoption of advanced treatment options. The French market benefits from strong healthcare infrastructure, increasing awareness about fungal infections, and the presence of key pharmaceutical companies. The country also shows significant progress in research and development of novel treatment approaches.

Onychomycosis Treatment Market in Asia-Pacific

The Asia-Pacific onychomycosis market demonstrates significant growth potential, driven by a large patient population, improving healthcare infrastructure, and increasing healthcare expenditure. The region encompasses diverse markets, including China, Japan, India, Australia, and South Korea, each with unique market characteristics and growth drivers. Rising awareness about fungal infections, a growing diabetic population, and increasing adoption of advanced treatment options contribute to market expansion.

Onychomycosis Treatment Market in China

China emerges as the largest market in the Asia-Pacific onychomycosis market, driven by its massive population base, improving healthcare infrastructure, and increasing healthcare expenditure. The country demonstrates strong growth in both traditional and advanced treatment options for onychomycosis. Rising awareness about fungal infections, a growing diabetic population, and increasing adoption of innovative treatment approaches contribute to market leadership. The country also shows significant progress in research and development activities related to onychomycosis treatment.

Onychomycosis Treatment Market in India

India represents the fastest-growing market in the Asia-Pacific region, supported by improving healthcare infrastructure, increasing awareness about fungal infections, and growing accessibility to treatment options. The country's large population base, rising prevalence of diabetes, and growing adoption of advanced treatment options drive market growth. Additionally, the presence of major pharmaceutical companies and increasing research activities contribute to market expansion. The country also demonstrates significant potential in developing cost-effective treatment solutions, with products like efinaconazole topical solution in India and competitive Jublia pricing in India.

Onychomycosis Treatment Market in Middle East & Africa

The Middle East & Africa onychomycosis treatment market shows steady growth potential, characterized by improving healthcare infrastructure and increasing awareness about fungal infections. The region encompasses diverse markets, including GCC countries and South Africa, with varying levels of healthcare accessibility and market maturity. Among these, GCC countries represent the largest market share, while South Africa demonstrates the fastest growth rate. The region's market growth is supported by increasing healthcare expenditure, rising prevalence of diabetes, and growing adoption of advanced treatment options.

Onychomycosis Treatment Market in South America

The South American onychomycosis treatment market exhibits promising growth potential, driven by improving healthcare infrastructure and increasing awareness about fungal infections. The region includes key markets such as Brazil and Argentina, with Brazil emerging as both the largest and fastest-growing market in the region. The market benefits from increasing healthcare expenditure, rising prevalence of diabetes, and growing adoption of advanced treatment options. The region also demonstrates significant progress in research and development activities related to onychomycosis treatment, particularly in exploring novel therapeutic approaches.

Onychomycosis Treatment Industry Overview

Top Companies in Onychomycosis Treatment Market

The onychomycosis treatment market features established pharmaceutical companies actively pursuing product innovation through advanced drug delivery systems and novel formulations. Companies are increasingly focusing on developing targeted therapies with improved efficacy and reduced treatment duration. Strategic partnerships and licensing agreements have become prevalent, particularly for geographic expansion and technology access. Operational agility is demonstrated through investments in R&D capabilities and manufacturing facilities, while companies are strengthening their distribution networks to enhance market presence. The industry has witnessed significant developments in both traditional drug-based treatments and emerging therapeutic approaches like photodynamic therapy and laser treatments, with companies maintaining diverse product portfolios to address varying patient needs and preferences.

Diverse Players Shape Dynamic Market Structure

The onychomycosis treatment market exhibits a mix of global pharmaceutical conglomerates and specialized dermatology-focused companies. Major pharmaceutical companies like Johnson & Johnson, Pfizer, and Bayer leverage their extensive research capabilities and global distribution networks, while specialized players such as Moberg Pharma and Medimetriks Pharmaceuticals focus on niche market segments with targeted product offerings. The market structure is characterized by strategic collaborations between large pharmaceutical companies and smaller biotechnology firms, particularly for developing innovative treatment solutions and accessing new geographical markets.


The industry demonstrates moderate market consolidation with ongoing merger and acquisition activities shaping the competitive landscape. Companies are actively pursuing strategic acquisitions to strengthen their product portfolios and expand their geographical presence, particularly in emerging markets. The market also witnesses significant licensing agreements and partnerships for commercialization rights, especially for novel treatment approaches and drug delivery technologies. Regional players maintain strong positions in their respective markets through established distribution networks and understanding of local healthcare systems.

Innovation and Market Access Drive Success

Success in the onychomycosis therapy market increasingly depends on developing innovative treatment solutions that offer improved efficacy and patient compliance. Companies need to invest in research and development to create differentiated products while maintaining cost-effectiveness. Building strong relationships with healthcare providers and establishing comprehensive distribution networks are crucial for market penetration. Regulatory compliance and safety documentation have become increasingly important, particularly for new treatment modalities and drug delivery systems. Companies must also focus on patient education and awareness programs to drive treatment adoption and adherence.


Market contenders can gain ground by focusing on underserved market segments and developing specialized treatment solutions for specific patient populations. Success factors include establishing strategic partnerships for technology access and market entry, particularly in emerging markets with growing healthcare infrastructure. Companies must address the challenge of treatment duration and efficacy while managing the risk of generic substitution. The increasing focus on personalized medicine and combination therapies presents opportunities for market differentiation. Future success will depend on balancing innovation with affordability while navigating evolving regulatory requirements and healthcare reimbursement policies.

Onychomycosis Treatment Market Leaders

  1. Bausch Health Companies Inc (Valeant Pharmaceuticals Inc)

  2. Galderma S.A.

  3. Novartis AG

  4. Pfizer, Inc

  5. Moberg Pharma AB

  6. *Disclaimer: Major Players sorted in no particular order
Onychomycosis Treatment Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Onychomycosis Treatment Market News

In April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) had received tentative approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.

In February 2021, Lupin Limited received the US Food and Drug Administration's approval for its Tavaborole Topical Solution for onychomycosis.

Onychomycosis Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Onychomycosis Globally
    • 4.2.2 Growing Awareness on the Potential Threats of Onychomycosis
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Onychomycosis Treatment Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Treatment Type
    • 5.1.1 Drugs
    • 5.1.2 Laser Therapy
    • 5.1.3 Photodynamic Therapy
  • 5.2 By Type
    • 5.2.1 Distal Subungual Onychomycosis
    • 5.2.2 White Superficial Onychomycosis
    • 5.2.3 Proximal Subungual Onychomycosis
    • 5.2.4 Other Types
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
    • 6.1.2 Galderma SA
    • 6.1.3 Novartis AG
    • 6.1.4 Pfizer Inc.
    • 6.1.5 Moberg Pharma AB
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Bayer AG
    • 6.1.8 Dr. Reddys Laboratories Ltd
    • 6.1.9 Cipla Ltd
    • 6.1.10 Lumenis Ltd
    • 6.1.11 Medimetriks Pharmaceuticals Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Onychomycosis Treatment Industry Segmentation

As per the scope of the report, onychomycosis is a fungal infection of the fingernails or toenails that may involve any component of the nail unit, including the matrix, bed, or plate. The onychomycosis treatment market is segmented by treatment type (drugs, laser therapy, and photodynamic therapy), type (distal subungual onychomycosis, white superficial onychomycosis, proximal subungual onychomycosis, and other types), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Type Drugs
Laser Therapy
Photodynamic Therapy
By Type Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Other Types
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Onychomycosis Treatment Market Research FAQs

How big is the Global Onychomycosis Treatment Market?

The Global Onychomycosis Treatment Market size is expected to reach USD 3.51 billion in 2025 and grow at a CAGR of 4.46% to reach USD 4.37 billion by 2030.

What is the current Global Onychomycosis Treatment Market size?

In 2025, the Global Onychomycosis Treatment Market size is expected to reach USD 3.51 billion.

Who are the key players in Global Onychomycosis Treatment Market?

Bausch Health Companies Inc (Valeant Pharmaceuticals Inc), Galderma S.A., Novartis AG, Pfizer, Inc and Moberg Pharma AB are the major companies operating in the Global Onychomycosis Treatment Market.

Which is the fastest growing region in Global Onychomycosis Treatment Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Onychomycosis Treatment Market?

In 2025, the North America accounts for the largest market share in Global Onychomycosis Treatment Market.

What years does this Global Onychomycosis Treatment Market cover, and what was the market size in 2024?

In 2024, the Global Onychomycosis Treatment Market size was estimated at USD 3.35 billion. The report covers the Global Onychomycosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Onychomycosis Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Onychomycosis Treatment Market Research

Mordor Intelligence provides a comprehensive analysis of the onychomycosis treatment market, utilizing extensive expertise in pharmaceutical and healthcare research. Our latest report explores global trends in fungal nail infection treatment and toenail fungus treatment. It covers key regions, including North America, Europe, Asia Pacific, and the Middle East and Africa onychomycosis markets. The analysis includes various therapeutic approaches, such as ciclopirox formulations, efinaconazole topical solution, and tavaborole 5 solution applications. Detailed insights are available in an easy-to-read report PDF format for download.

The report provides stakeholders with crucial intelligence on onychomycosis therapy developments, treatment techniques, and emerging opportunities across different distribution channels. Our analysis addresses both dermatophytic onychomycosis treatment and related conditions, such as onycholysis and paronychia treatment. Healthcare providers, pharmaceutical companies, and investors can benefit from our detailed examination of topical treatment options, pricing dynamics, and regional market variations. The report offers actionable insights into nail fungus therapy advancements, including developments in markets such as Jublia in Mexico and efinaconazole solutions in India, supporting informed decision-making across the therapeutic landscape.